New York Life Investment Management LLC Acquires 13,458 Shares of Boston Scientific Corporation $BSX

New York Life Investment Management LLC grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 6.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 214,666 shares of the medical equipment provider’s stock after acquiring an additional 13,458 shares during the quarter. New York Life Investment Management LLC’s holdings in Boston Scientific were worth $20,468,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the second quarter valued at approximately $26,000. Murphy & Mullick Capital Management Corp grew its position in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares in the last quarter. United Community Bank increased its stake in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the period. Colonial Trust Co SC raised its holdings in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 231 shares in the last quarter. Finally, Bangor Savings Bank lifted its position in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Price Performance

Shares of BSX stock opened at $53.61 on Friday. The business has a fifty day simple moving average of $63.79 and a 200 day simple moving average of $82.00. The company has a market cap of $79.67 billion, a P/E ratio of 22.43, a P/E/G ratio of 0.97 and a beta of 0.62. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a twelve month low of $52.75 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Weiss Ratings lowered Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday. Barclays cut their price objective on shares of Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. UBS Group reduced their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. Finally, Robert W. Baird cut their price target on shares of Boston Scientific from $86.00 to $78.00 and set an “outperform” rating for the company in a report on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $93.91.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific is being highlighted for strong international growth, with APAC momentum, FARAPULSE adoption, and new approvals in Europe and China helping expand its global footprint. Here’s How Boston Scientific Is Expanding Its Global Growth
• Positive Sentiment: Jim Cramer said he would “hold” BSX, implying he sees the company as a stock investors may want to keep rather than sell, which can help sentiment. Jim Cramer on Boston Scientific: “I Think You Gotta Hold It”
• Positive Sentiment: Recent commentary continues to point to Boston Scientific’s cardiovascular franchise as a long-term growth driver, with products like FARAPULSE and WATCHMAN supporting demand. Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?
• Neutral Sentiment: The company treated its first patient with Seismiq IVL in the ELEGANCE registry, a small but positive clinical/commercial update that adds to its product pipeline narrative. Boston Scientific treats first patient with Seismiq IVL in ELEGANCE registry
• Neutral Sentiment: Boston Scientific filed a shelf registration tied to an ESOP-related offering and approved governance changes, which may help align incentives but also adds dilution/watch-list considerations for investors. Is Boston Scientific (BSX) Quietly Recasting Its Ownership Structure To Sharpen Its Investment Story?
• Negative Sentiment: Some reports say BSX has fallen amid concerns that its growth may not be durable, which likely weighed on sentiment. Boston Scientific (BSX) Fell Amid Concerns Over Growth Durability
• Negative Sentiment: Insiders reportedly sold about $1.2 million of shares, which can signal caution and add to investor concern during a weak stretch for the stock. Boston Scientific Insiders Sold US$1.2m Of Shares Suggesting Hesitancy
• Negative Sentiment: MarketWatch noted that Boston Scientific underperformed peers, reinforcing the view that investor sentiment remains cautious despite the company’s long-term growth story. Boston Scientific Corp. stock underperforms Wednesday when compared to competitors

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.